Page 4 - Mark Swallow News Today

("Nordic Nanovector" or the "Company") announces the progress it has made in designing and developing a...

ROME Therapeuticsand Enara Bio, two leading biotechnology companies focused on developing novel medicines driven by insights to the dark genome, today announced that they will host the inaugural Dark

- Frederic Chereau named Chairman of the Board - Seasoned entrepreneur, Dr Claudia Mitchell, appointed Non-executive Director PARIS, Oct. 20, 2022 /PRNewswire/ -- Coave Therapeutics

PARIS, Oct. 11, 2022 /PRNewswire/ -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform

/PRNewswire/ -- Coave Therapeutics (Coave), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central...

PARIS, Sept. 20, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System)

PARIS, Sept. 16, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform

/PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug...

/PRNewswire/ -- Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane...

/PRNewswire/ -- Coave Therapeutics (Coave), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central...